New Data: Nanoprimer Improves DNA Therapy, Reduces Toxicity
Nanobiotix presented new preclinical data at AACR showing that an intravenous “nanoprimer” administered before lipid nanoparticle–delivered recombinant DNA increased...
eClinical Tech News
Achieve Life Sciences Secures Up To $354M in Private Placement
Achieve Life Sciences has secured up to $354 million to carry its nicotine-dependence franchise through a pivotal inflection point,...
Eurobio Scientific to Acquire CareDx Transplant Lab Division
Eurobio Scientific has signed a definitive agreement to acquire CareDx’s Lab Products division for approximately €145 million in cash,...
First Patient Enrolled in Pivotal Phase 3 BV100 Trial
BioVersys has dosed the first patient in its global pivotal Phase 3 RIV-TARGET trial evaluating BV100, an intravenous rifabutin...
AiCuris’ Pritelivir Granted FDA Priority Review, New Data
The FDA has granted Priority Review to AiCuris’ new drug application for pritelivir, an oral helicase-primase inhibitor for refractory...
Remedy Plan Therapeutics Appoints New Finance, Business Chief
Remedy Plan Therapeutics has appointed Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer as the company transitions...
Nurix Announces Q1 2026 Financials & Corporate Update
Nurix Therapeutics is moving its BTK degrader, bexobrutideg, onto a registrational track in relapsed/refractory chronic lymphocytic leukemia with an...
Novabridge Announces Full Year 2025 Financial Results
NovaBridge Biosciences reported year-end 2025 results and advanced two mid-stage assets: givastomig, a CLDN18.2 x 4-1BB bispecific antibody in...
NovaBridge Releases New Full Year 2025 Financial Results
NovaBridge Biosciences reported full-year 2025 results and set out a tighter, higher-stakes development agenda around two lead assets. In...
Coeptis Announces Successful Nasdaq Approval for Z Squared
Nasdaq has approved, subject to closing conditions, the listing of the post-merger company formed by Coeptis Therapeutics and Z...